{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:30:56Z","timestamp":1793521856417,"version":"4.5.0"},"reference-count":84,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel\u2019s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.<\/jats:p>","DOI":"10.6004\/jnccn.2025.0007","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:04:44Z","timestamp":1739358284000},"page":"2-11","source":"Crossref","is-referenced-by-count":223,"title":["NCCN Guidelines\u00ae Insights: Head and Neck Cancers, Version 2.2025"],"prefix":"10.6004","volume":"23","author":[{"given":"A. Dimitrios","family":"Colevas","sequence":"first","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Cmelak","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Spencer","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Adkins","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Birkeland","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Brizel","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Busse","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy J.","family":"Caudell","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Durm","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Fakhry","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Galloway","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Geiger","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura L.","family":"Gillison","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Glastonbury","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley L.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying J.","family":"Hitchcock","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Juloori","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kase","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Leizman","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Maghami","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren K.","family":"Mell","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat B.","family":"Mittal","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan A.","family":"Pinto","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Price","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Rocco","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina P.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schwartz","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sher","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maie St.","family":"John","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[{"name":"Yale Cancer Center Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Worden","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine Yang","family":"Bruce","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue S.","family":"Yom","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Zhen","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Montgomery","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Darlow","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2024","author":"Ferlay J","unstructured":"Ferlay J, Ervik M, Lam F,  Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2024. Accessed December 20, 2024. Available at: https:\/\/gco.iarc.who.int\/today\/en"},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen W","year":"2016","unstructured":"Chen W, Zheng R, Baade PD,  Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115\u2013132."},{"key":"B3","series-title":"Lancet","first-page":"1012","article-title":"Nasopharyngeal carcinoma","volume":"387","author":"Chua MLK","year":"2016","unstructured":"Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet 2016;387:1012\u20131024."},{"key":"B4","series-title":"N Engl J Med","first-page":"693","article-title":"Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma","volume":"333","author":"Pathmanathan R","year":"1995","unstructured":"Pathmanathan R, Prasad U, Sadler R,  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693\u2013698."},{"key":"B5","series-title":"Lancet","first-page":"64","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen YP","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT,  Nasopharyngeal carcinoma. Lancet 2019;394:64\u201380."},{"key":"B6","series-title":"J Clin Oncol","first-page":"3356","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective","volume":"33","author":"Lee AW","year":"2015","unstructured":"Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 2015;33:3356\u20133364."},{"key":"B7","series-title":"J Clin Oncol","first-page":"1342","article-title":"Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study","volume":"8","author":"Al-Sarraf M","year":"1990","unstructured":"Al-Sarraf M, Pajak TF, Cooper JS,  Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol 1990;8:1342\u20131351."},{"key":"B8","series-title":"J Clin Oncol","first-page":"1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf M","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG,  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310\u20131317."},{"key":"B9","series-title":"J Natl Cancer Inst","first-page":"536","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma","volume":"97","author":"Chan AT","year":"2005","unstructured":"Chan AT, Leung SF, Ngan RK,  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536\u2013539."},{"key":"B10","series-title":"J Clin Oncol","first-page":"631","article-title":"Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival","volume":"21","author":"Lin JC","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY,  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631\u2013637."},{"key":"B11","series-title":"J Clin Oncol","first-page":"6730","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee J","year":"2005","unstructured":"Wee J, Tan EH, Tai BC,  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730\u20136738."},{"key":"B12","series-title":"Cancer","first-page":"4147","article-title":"A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity","volume":"123","author":"Lee AWM","year":"2017","unstructured":"Lee AWM, Tung SY, Ng WT,  A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer 2017;123:4147\u20134157."},{"key":"B13","series-title":"Lancet Oncol","first-page":"163","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen L","year":"2012","unstructured":"Chen L, Hu CS, Chen XZ,  Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163\u2013171."},{"key":"B14","series-title":"Curr Probl Cancer","first-page":"302","article-title":"Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: a meta-analysis of the published literature","volume":"42","author":"Wang S","year":"2018","unstructured":"Wang S, Li S, Shen L. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: a meta-analysis of the published literature. Curr Probl Cancer 2018;42:302\u2013318."},{"key":"B15","series-title":"PLoS One","first-page":"e0194733","article-title":"The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a systematic review and meta-analysis","volume":"13","author":"Liu F","year":"2018","unstructured":"Liu F, Jin T, Liu L,  The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a systematic review and meta-analysis. PLoS One 2018;13:e0194733."},{"key":"B16","series-title":"J Cancer","first-page":"287","article-title":"Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients","volume":"8","author":"Xu C","year":"2017","unstructured":"Xu C, Zhang LH, Chen YP,  Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. J Cancer 2017;8:287\u2013297."},{"key":"B17","series-title":"Front Oncol","first-page":"1314","article-title":"Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial","volume":"10","author":"Huang X","year":"2020","unstructured":"Huang X, Chen X, Zhao C,  Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. Front Oncol 2020;10:1314."},{"key":"B18","series-title":"JAMA","first-page":"728","article-title":"Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial","volume":"328","author":"Tang LL","year":"2022","unstructured":"Tang LL, Guo R, Zhang N,  Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA 2022;328:728\u2013736."},{"key":"B19","series-title":"Lancet Oncol","first-page":"645","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard P","year":"2015","unstructured":"Blanchard P, Lee A, Marguet S,  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16:645\u2013655."},{"key":"B20","series-title":"Eur J Cancer","first-page":"87","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang Q","year":"2019","unstructured":"Yang Q, Cao SM, Guo L,  Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 2019;119:87\u201396."},{"key":"B21","series-title":"N Engl J Med","first-page":"1124","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ,  Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019;381:1124\u20131135."},{"key":"B22","series-title":"J Clin Oncol","first-page":"498","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed L","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM,  What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017;35:498\u2013505."},{"key":"B23","series-title":"Clin Cancer Res","first-page":"1824","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials","volume":"24","author":"Chen YP","year":"2018","unstructured":"Chen YP, Tang LL, Yang Q,  Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 2018;24:1824\u20131833."},{"key":"B24","series-title":"Radiother Oncol","first-page":"10","article-title":"Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and meta-analysis","volume":"129","author":"Tan TH","year":"2018","unstructured":"Tan TH, Soon YY, Cheo T,  Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and meta-analysis. Radiother Oncol 2018;129:10\u201317."},{"key":"B25","series-title":"Medicine (Baltimore)","first-page":"e19360","article-title":"The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials","volume":"99","author":"Wang P","year":"2020","unstructured":"Wang P, Zhang M, Ke C, Cai C. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2020;99:e19360."},{"key":"B26","series-title":"J Clin Oncol","first-page":"840","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen YP","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK,  Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol 2021;39:840\u2013859."},{"key":"B27","series-title":"Lancet Oncol","first-page":"611","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"24","author":"Petit C","year":"2023","unstructured":"Petit C, Lee A, Ma J,  Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol 2023;24:611\u2013623."},{"key":"B28","series-title":"Theranostics","first-page":"4825","article-title":"The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two\/three-dimensional radiotherapy to intensity-modulated radiotherapy: a network meta-analysis","volume":"7","author":"You R","year":"2017","unstructured":"You R, Cao YS, Huang PY,  The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two\/three-dimensional radiotherapy to intensity-modulated radiotherapy: a network meta-analysis. Theranostics 2017;7:4825\u20134835."},{"key":"B29","series-title":"Cancer","first-page":"3674","article-title":"NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma","volume":"126","author":"Lee AWM","year":"2020","unstructured":"Lee AWM, Ngan RKC, Ng WT,  NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer 2020;126:3674\u20133688."},{"key":"B30","series-title":"JAMA Oncol","first-page":"456","article-title":"Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial","volume":"10","author":"Dai J","year":"2024","unstructured":"Dai J, Zhang B, Su Y,  Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol 2024;10:456\u2013463."},{"key":"B31","series-title":"JAMA Oncol","first-page":"1776","article-title":"Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial","volume":"8","author":"Miao J","year":"2022","unstructured":"Miao J, Wang L, Tan SH,  Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol 2022;8:1776\u20131785."},{"key":"B32","series-title":"JAMA Oncol","first-page":"553","article-title":"Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial","volume":"8","author":"Liu GY","year":"2022","unstructured":"Liu GY, Li WZ, Wang DS,  Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial. JAMA Oncol 2022;8:553\u2013561."},{"key":"B33","series-title":"Lancet","first-page":"303","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen YP","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q,  Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 2021;398:303\u2013313."},{"key":"B34","series-title":"Cancer Cell","first-page":"1061","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang Y","year":"2023","unstructured":"Yang Y, Pan J, Wang H,  Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 2023;41:1061\u20131072.e4."},{"key":"B35","series-title":"Lancet","first-page":"2720","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu X","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY,  Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 2024;403:2720\u20132731."},{"key":"B36","series-title":"J Natl Compr Canc Netw","first-page":"913","article-title":"Validation of the 8th edition of the UICC\/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era","volume":"15","author":"Tang LL","year":"2017","unstructured":"Tang LL, Chen YP, Mao YP,  Validation of the 8th edition of the UICC\/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw 2017;15:913\u2013919."},{"key":"B37","series-title":"Cancer","first-page":"79","article-title":"Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma","volume":"125","author":"Guo R","year":"2019","unstructured":"Guo R, Tang LL, Mao YP,  Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 2019;125:79\u201389."},{"key":"B38","series-title":"Lancet Oncol","first-page":"1509","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun Y","year":"2016","unstructured":"Sun Y, Li WF, Chen NY,  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016;17:1509\u20131520."},{"key":"B39","series-title":"J Clin Oncol","first-page":"2420","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Chen L, Hu GQ,  Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol 2022;40:2420\u20132425."},{"key":"B40","series-title":"Head Neck Oncol","first-page":"30","article-title":"Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma","volume":"3","author":"Dechaphunkul T","year":"2011","unstructured":"Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. Head Neck Oncol 2011;3:30."},{"key":"B41","series-title":"Radiol Oncol","first-page":"155","article-title":"Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma","volume":"49","author":"Songthong A","year":"2015","unstructured":"Songthong A, Chakkabat C, Kannarunimit D, Lertbutsayanukul C. Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. Radiol Oncol 2015;49:155\u2013162."},{"key":"B42","series-title":"Eur J Cancer","first-page":"1399","article-title":"Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial","volume":"43","author":"Chitapanarux I","year":"2007","unstructured":"Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P,  Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007;43:1399\u20131406."},{"key":"B43","series-title":"Radiother Oncol","first-page":"139","article-title":"Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy","volume":"124","author":"Rusthoven CG","year":"2017","unstructured":"Rusthoven CG, Lanning RM, Jones BL,  Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 2017;124:139\u2013146."},{"key":"B44","series-title":"Case Rep Oncol","first-page":"392","article-title":"Long-term disease-free survival of a patient with oligometastatic nasopharyngeal carcinoma treated with radiotherapy alone","volume":"11","author":"Chua GWY","year":"2018","unstructured":"Chua GWY, Chua ET. Long-term disease-free survival of a patient with oligometastatic nasopharyngeal carcinoma treated with radiotherapy alone. Case Rep Oncol 2018;11:392\u2013398."},{"key":"B45","series-title":"Chin J Cancer","first-page":"787","article-title":"The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases","volume":"29","author":"Ma J","year":"2010","unstructured":"Ma J, Wen ZS, Lin P,  The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases. Chin J Cancer 2010;29:787\u2013795."},{"key":"B46","series-title":"JAMA Oncol","first-page":"1345","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You R","year":"2020","unstructured":"You R, Liu YP, Huang PY,  Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol 2020;6:1345\u20131352."},{"key":"B47","series-title":"Lancet","first-page":"1883","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang L","year":"2016","unstructured":"Zhang L, Huang Y, Hong S,  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016;388:1883\u20131892."},{"key":"B48","series-title":"J Clin Oncol","first-page":"3273","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study","volume":"39","author":"Hong S","year":"2021","unstructured":"Hong S, Zhang Y, Yu G,  Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study. J Clin Oncol 2021;39:3273\u20133282."},{"key":"B49","series-title":"Cancer Invest","first-page":"182","article-title":"Evaluation of the combination of docetaxel\/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group phase II study","volume":"25","author":"Samlowski WE","year":"2007","unstructured":"Samlowski WE, Moon J, Kuebler JP,  Evaluation of the combination of docetaxel\/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group phase II study. Cancer Invest 2007;25:182\u2013188."},{"key":"B50","series-title":"J Clin Oncol","first-page":"3562","article-title":"Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group","volume":"23","author":"Gibson MK","year":"2005","unstructured":"Gibson MK, Li Y, Murphy B,  Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562\u20133567."},{"key":"B51","series-title":"J Clin Oncol","first-page":"1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study","volume":"10","author":"Forastiere AA","year":"1992","unstructured":"Forastiere AA, Metch B, Schuller DE,  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245\u20131251."},{"key":"B52","series-title":"J Clin Oncol","first-page":"3568","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan ATC","year":"2005","unstructured":"Chan ATC, Hsu MM, Goh BC,  Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568\u20133576."},{"key":"B53","series-title":"J Cancer Res Clin Oncol","first-page":"1717","article-title":"Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma","volume":"138","author":"Jin Y","year":"2012","unstructured":"Jin Y, Cai XY, Shi YX,  Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012;138:1717\u20131725."},{"key":"B54","series-title":"J Clin Oncol","first-page":"257","article-title":"A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck","volume":"10","author":"Jacobs C","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garcia E,  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257\u2013263."},{"key":"B55","series-title":"J Clin Oncol","first-page":"8646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness B","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W,  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646\u20138654."},{"key":"B56","series-title":"Acta Otolaryngol","first-page":"1294","article-title":"Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients","volume":"129","author":"Grau JJ","year":"2009","unstructured":"Grau JJ, Caballero M, Verger E,  Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129:1294\u20131299."},{"key":"B57","series-title":"Eur J Cancer","first-page":"2071","article-title":"Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer","volume":"40","author":"Guardiola E","year":"2004","unstructured":"Guardiola E, Peyrade F, Chaigneau L,  Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071\u20132076."},{"key":"B58","series-title":"Ann Oncol","first-page":"533","article-title":"Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group","volume":"5","author":"Catimel G","year":"1994","unstructured":"Catimel G, Verweij J, Mattijssen V,  Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533\u2013537."},{"key":"B59","series-title":"J Clin Oncol","first-page":"1864","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]","volume":"27","author":"Stewart JS","year":"2009","unstructured":"Stewart JS, Cohen EE, Licitra L,  Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864\u20131871."},{"key":"B60","series-title":"J Natl Compr Canc Netw","first-page":"681","article-title":"Current recommendations for systemic therapy of recurrent and\/or metastatic head and neck squamous cell cancer","volume":"9","author":"Fury MG","year":"2011","unstructured":"Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and\/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2011;9:681\u2013689."},{"key":"B61","series-title":"Curr Treat Options Oncol","first-page":"35","article-title":"Current treatment options for metastatic head and neck cancer","volume":"13","author":"Price KA","year":"2012","unstructured":"Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13:35\u201346."},{"key":"B62","series-title":"Br J Cancer","first-page":"1687","article-title":"Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment","volume":"102","author":"Martinez-Trufero J","year":"2010","unstructured":"Martinez-Trufero J, Isla D, Adansa JC,  Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102:1687\u20131691."},{"key":"B63","series-title":"Cancer Chemother Pharmacol","first-page":"33","article-title":"Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy","volume":"61","author":"Zhang L","year":"2008","unstructured":"Zhang L, Zhang Y, Huang PY,  Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:33\u201338."},{"key":"B64","series-title":"J Clin Oncol","first-page":"2644","article-title":"Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"24","author":"Colevas AD.","year":"2006","unstructured":"Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644\u20132652."},{"key":"B65","series-title":"Cancer","first-page":"2270","article-title":"Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390)","volume":"82","author":"Forastiere AA","year":"1998","unstructured":"Forastiere AA, Shank D, Neuberg D,  Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270\u20132274."},{"key":"B66","series-title":"JAMA","first-page":"1961","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai HQ","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D,  Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 2023;330:1961\u20131970."},{"key":"B67","series-title":"J Clin Oncol","first-page":"704","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang FH","year":"2021","unstructured":"Wang FH, Wei XL, Feng J,  Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 2021;39:704\u2013712."},{"key":"B68","series-title":"J Immunother Cancer","first-page":"e000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen L","year":"2020","unstructured":"Shen L, Guo J, Zhang Q,  Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study. J Immunother Cancer 2020;8:e000437."},{"key":"B69","series-title":"Lancet Oncol","first-page":"1162","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang Y","year":"2021","unstructured":"Yang Y, Qu S, Li J,  Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22:1162\u20131174."},{"key":"B70","series-title":"J Clin Oncol","first-page":"4050","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu C","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S,  Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017;35:4050\u20134056."},{"key":"B71","series-title":"Lancet Oncol","first-page":"1353","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J,  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353\u20131365."},{"key":"B72","series-title":"J Clin Oncol","first-page":"Abstract 6025","article-title":"An open-label, multicohort, phase I\/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC)","volume":"35","author":"Delord JP","year":"2017","unstructured":"Delord JP, Hollebecque A, De Boer JP,  An open-label, multicohort, phase I\/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC). J Clin Oncol 2017;35(Suppl):Abstract 6025."},{"key":"B73","series-title":"In Vivo","first-page":"2967","article-title":"Investigation of the efficacy and safety of nivolumab in recurrent and metastatic nasopharyngeal carcinoma","volume":"34","author":"Sato H","year":"2020","unstructured":"Sato H, Fushimi C, Okada T,  Investigation of the efficacy and safety of nivolumab in recurrent and metastatic nasopharyngeal carcinoma. In Vivo 2020;34:2967\u20132972."},{"key":"B74","series-title":"J Clin Oncol","first-page":"1412","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma BBY","year":"2018","unstructured":"Ma BBY, Lim WT, Goh BC,  Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 2018;36:1412\u20131418."},{"key":"B75","series-title":"Lancet Oncol","first-page":"172","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"Lee NY","year":"2012","unstructured":"Lee NY, Zhang Q, Pfister DG,  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012;13:172\u2013180."},{"key":"B76","series-title":"J Clin Oncol","first-page":"2021","article-title":"Reduced-volume irradiation of uninvolved neck in patients with nasopharyngeal cancer: updated results from an open-label, noninferiority, multicenter, randomized phase III trial","volume":"42","author":"Huang CL","year":"2024","unstructured":"Huang CL, Zhang N, Jiang W,  Reduced-volume irradiation of uninvolved neck in patients with nasopharyngeal cancer: updated results from an open-label, noninferiority, multicenter, randomized phase III trial. J Clin Oncol 2024;42:2021\u20132025."},{"key":"B77","series-title":"Lancet Oncol","first-page":"479","article-title":"Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial","volume":"23","author":"Tang LL","year":"2022","unstructured":"Tang LL, Huang CL, Zhang N,  Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol 2022;23:479\u2013490."},{"key":"B78","series-title":"Int J Radiat Oncol Biol Phys","first-page":"725","article-title":"Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer","volume":"75","author":"Salama JK","year":"2009","unstructured":"Salama JK, Haddad RI, Kies MS,  Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;75:725\u2013733."},{"key":"B79","series-title":"Lancet Oncol","first-page":"381","article-title":"Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Liu YP","year":"2021","unstructured":"Liu YP, Wen YH, Tang J,  Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:381\u2013390."},{"key":"B80","series-title":"Lancet","first-page":"917","article-title":"Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"401","author":"You R","year":"2023","unstructured":"You R, Liu YP, Xie YL,  Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2023;401:917\u2013927."},{"key":"B81","series-title":"Int J Radiat Oncol Biol Phys","first-page":"682","article-title":"International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma","volume":"110","author":"Ng WT","year":"2021","unstructured":"Ng WT, Soong YL, Ahn YC,  International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2021;110:682\u2013695."},{"key":"B82","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1117","article-title":"Reirradiation of head and neck cancers with intensity modulated radiation therapy: outcomes and analyses","volume":"95","author":"Takiar V","year":"2016","unstructured":"Takiar V, Garden AS, Ma D,  Reirradiation of head and neck cancers with intensity modulated radiation therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys 2016;95:1117\u20131131."},{"key":"B83","series-title":"J Radiat Res","first-page":"288","article-title":"Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer","volume":"57","author":"Yamazaki H","year":"2016","unstructured":"Yamazaki H, Ogita M, Himei K,  Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer. J Radiat Res 2016;57:288\u2013293."},{"key":"B84","series-title":"Int J Radiat Oncol Biol Phys","first-page":"130","article-title":"Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy","volume":"76","author":"Koutcher L","year":"2010","unstructured":"Koutcher L, Lee N, Zelefsky M,  Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 2010;76:130\u2013137."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/2\/article-p2.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/2\/article-p2.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/2\/article-p2.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:04:44Z","timestamp":1739358284000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/2\/article-p2.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":84,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.0007","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}